Astellas and aviadobio announce exclusive option and license agreement for gene therapy avb-101 targeting frontotemporal dementia and other indications

Astellas receives an exclusive option to license avb-101, an investigational, aav-based gene therapy in phase 1/2 development  aviadobio receives $20 million equity investment, up to $30 million in upfront payments and is eligible to receive up to $2.18 billion in license fees and milestone payments plus royalties if astellas exercises its option london and tokyo , oct. 8, 2024 /prnewswire/ -- aviadobio ltd. ("aviadobio") and astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") today announced an exclusive option and license agreement for avb-101, an investigational, aav-based gene therapy in phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (ftd-grn).
AVB Ratings Summary
AVB Quant Ranking